Human Anti-Hepatitis C Virus Antibody, Anti-HCV ELISA Kit (DEIA015)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma
Species Reactivity
Intended Use
The Human Anti-Hepatitis C Virus Antibody, Anti-HCV ELISA Kit is designed for the detection of antibodies to Hepatitis C virus in human serum or plasma.
Contents of Kit
1. Microwell plate: 1 x 96 wells
2. Conjugate: 2 x 7.5 mL
3. Positive control: 1 x 1.0 mL
4. Negative control: 1 x 1.0 mL
5. Wash Solution(25X): 1 x 80 mL
6. Chromogen A: 1 x 8 mL
7. Chromogen B: 1 x 8 mL
8. Stopping Solution: 1 x 7 mL
9. Specimen Diluent: 1 x 20 mL
Store the kit reagents at 2-8°C. For more detailed information, please download the following document on our website.


Have you cited DEIA015 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice


Authors: Brown, Richard J. P.; Tegtmeyer, Birthe; Sheldon, Julie; Khera, Tanvi; Anggakusuma; Todt, Daniel; Vieyres, Gabrielle; Weller, Romy; Joecks, Sebastian; Zhang, Yudi; Sake, Svenja; Bankwitz, Dorothea; Welsch, Kathrin; Ginkel, Corinne; Engelmann, Michael; Gerold, Gisa; Steinmann, Eike; Yuan, Qinggong; Ott, Michael; Vondran, Florian W. R.; Krey, Thomas; Stroeh, Luisa J.; Miskey, Csaba; Ivics, Zoltan; Herder, Vanessa; Baumgaertner, Wolfgang; Lauber, Chris; Seifert, Michael; Tarr, Alexander W.; McClure, C. Patrick; Randall, Glenn; Baktash, Yasmine; Ploss, Alexander; Thi, Viet Loan Dao; Michailidis, Eleftherios; Saeed, Mohsan; Verhoye, Lieven; Meuleman, Philip; Goedecke, Natascha; Wirth, Dagmar; Rice, Charles M.; Pietschmann, Thomas

Hepatitis C virus (HCV) has no animal reservoir, infecting only humans. To investigate species barrier determinants limiting infection of rodents, murine liver complementary DNA library screening was performed, identifying transmembrane proteins Cd302 and Cr1l as potent restrictors of HCV propagation. Combined ectopic expression in human hepatoma cells impeded HCV uptake and cooperatively mediated transcriptional dysregulation of a noncanonical program of immunity genes. Murine hepatocyte expression of both factors was constitutive and not interferon inducible, while differences in liver expression and the ability to restrict HCV were observed between the murine orthologs and their human counterparts. Genetic ablation of endogenous Cd302 expression in human HCV entry factor transgenic mice increased hepatocyte permissiveness for an adapted HCV strain and dysregulated expression of metabolic process and host defense genes. These findings highlight human-mouse differences in liver-intrinsic antiviral immunity and facilitate the development of next-generation murine models for preclinical testing of HCV vaccine candidates.

Synthesis, biological evaluation and in silico modeling of novel pangenotypic NS5A inhibitors


Authors: Ivashchenko, Andrey A.; Ivanenkov, Yan A.; Aladinskiy, Vladimir A.; Karapetian, Ruben N.; Koryakova, Angela G.; Ryakhovskiy, Alexey A.; Mitkin, Oleg D.; Kravchenko, Dmitry, V; Savchuk, Nikolai P.; Zagribelnyy, Bogdan A.; Ivashchenko, Alexander, V

A series of novel small-molecule pan-genotypic hepatitis C virus (HCV) NS5A inhibitors with picomolar activity containing 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}buta-1,3-diyn-1-yl) phenyl]-1H-imidazole core was designed based on molecular modeling study and SAR analysis. The constructed in silico model and docking study provide a deep insight into the binding mode of this type of NS5A inhibitors. Based on the predicted binding interface we have prioritized the most crucial diversity points responsible for improving antiviral activity. The synthesized molecules were tested in a cell-based assay, and compound 1.12 showed an EC50 value in the range of 2.9-34 pM against six genotypes of NS5A HCV, including gT3a, and demonstrated favorable pharmacokinetic profile in rats. This lead compound can be considered as an attractive candidate for further clinical evaluation.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket